Cartesian Therapeutics Stock Performance
| RNAC Stock | 7.24 0.18 2.43% |
The firm shows a Beta (market volatility) of 0.21, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cartesian Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cartesian Therapeutics is expected to be smaller as well. At this point, Cartesian Therapeutics has a negative expected return of -0.2%. Please make sure to confirm Cartesian Therapeutics' daily balance of power, and the relationship between the skewness and day typical price , to decide if Cartesian Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Cartesian Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's basic indicators remain sound and the latest tumult on Wall Street may also be a sign of longer-term gains for the firm shareholders. ...more
Actual Historical Performance (%)
One Day Return 0.82 | Five Day Return (2.37) | Year To Date Return 9.76 | Ten Year Return (98.23) | All Time Return (98.23) |
Last Split Factor 1:30 | Last Split Date 2024-04-05 |
1 | Cartesian Therapeutics Announces Leadership Changes - The Globe and Mail | 10/31/2025 |
2 | Disposition of 20000 shares by Singer Michael of Cartesian Therapeutics subject to Rule 16b-3 | 11/18/2025 |
3 | Disposition of 7500 shares by Emily English of Cartesian Therapeutics at 3.3 subject to Rule 16b-3 | 11/28/2025 |
4 | Acquisition by Springer Timothy A of 5181 shares of Cartesian Therapeutics at 18.9996 subject to Rule 16b-3 | 12/05/2025 |
5 | Cartesian Therapeutics Sees Share Boost After Insider Pur - GuruFocus | 12/09/2025 |
6 | Insider Trading | 12/16/2025 |
7 | Aug Wrap Why Cartesian Therapeutics Inc. stock could be top winner - Weekly Gains Summary Daily Volume Surge Trade Alerts - DonanmHaber | 12/19/2025 |
8 | Acquisition by Kalayoglu Murat of 7800 shares of Cartesian Therapeutics at 6.76 subject to Rule 16b-3 | 01/02/2026 |
9 | Top Brass Makes Big Moves as Cartesian Therapeutics Executives Cash In on Shares - TipRanks | 01/08/2026 |
10 | Cartesian Therapeutics, Inc. Upgraded to Buy What Does It Mean for the Stock | 01/14/2026 |
| Begin Period Cash Flow | 78.3 M | |
| Total Cashflows From Investing Activities | -8.7 M |
Cartesian | Build AI portfolio with Cartesian Stock |
Cartesian Therapeutics Relative Risk vs. Return Landscape
If you would invest 899.00 in Cartesian Therapeutics on October 22, 2025 and sell it today you would lose (157.00) from holding Cartesian Therapeutics or give up 17.46% of portfolio value over 90 days. Cartesian Therapeutics is currently does not generate positive expected returns and assumes 4.9386% risk (volatility on return distribution) over the 90 days horizon. In different words, 44% of stocks are less volatile than Cartesian, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cartesian Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cartesian Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cartesian Therapeutics, and traders can use it to determine the average amount a Cartesian Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0396
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | RNAC |
Based on monthly moving average Cartesian Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cartesian Therapeutics by adding Cartesian Therapeutics to a well-diversified portfolio.
Cartesian Therapeutics Fundamentals Growth
Cartesian Stock prices reflect investors' perceptions of the future prospects and financial health of Cartesian Therapeutics, and Cartesian Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cartesian Stock performance.
| Return On Equity | -70.29 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (46.61) % | ||||
| Current Valuation | 62.17 M | ||||
| Shares Outstanding | 26 M | ||||
| Price To Book | 31.26 X | ||||
| Price To Sales | 176.85 X | ||||
| Revenue | 38.91 M | ||||
| Gross Profit | (51.76 M) | ||||
| EBITDA | (75.99 M) | ||||
| Net Income | (77.42 M) | ||||
| Cash And Equivalents | 106.44 M | ||||
| Total Debt | 13.98 M | ||||
| Book Value Per Share | (1.38) X | ||||
| Cash Flow From Operations | (23.67 M) | ||||
| Earnings Per Share | (1.33) X | ||||
| Market Capitalization | 192.95 M | ||||
| Total Asset | 435.02 M | ||||
| Retained Earnings | (692.07 M) | ||||
| Working Capital | 193.65 M | ||||
About Cartesian Therapeutics Performance
By analyzing Cartesian Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Cartesian Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cartesian Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cartesian Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.38) | (0.40) | |
| Return On Capital Employed | (0.10) | (0.10) | |
| Return On Assets | (0.16) | (0.17) | |
| Return On Equity | 10.24 | 10.76 |
Things to note about Cartesian Therapeutics performance evaluation
Checking the ongoing alerts about Cartesian Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cartesian Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cartesian Therapeutics generated a negative expected return over the last 90 days | |
| Cartesian Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 38.91 M. Net Loss for the year was (77.42 M) with loss before overhead, payroll, taxes, and interest of (51.76 M). | |
| Cartesian Therapeutics currently holds about 106.44 M in cash with (23.67 M) of positive cash flow from operations. | |
| Cartesian Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 61.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from zacks.com: Cartesian Therapeutics, Inc. Upgraded to Buy What Does It Mean for the Stock |
- Analyzing Cartesian Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cartesian Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Cartesian Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cartesian Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cartesian Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cartesian Therapeutics' stock. These opinions can provide insight into Cartesian Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cartesian Stock analysis
When running Cartesian Therapeutics' price analysis, check to measure Cartesian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cartesian Therapeutics is operating at the current time. Most of Cartesian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cartesian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cartesian Therapeutics' price. Additionally, you may evaluate how the addition of Cartesian Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |